Related Experiment Video
Updated: Mar 1, 2026
Author Spotlight: Optimizing Digital Droplet PCR Method for Accurate Adeno-Associated Viral Genome Quantification
Published on: October 11, 2024
Promise of adeno-associated virus as a gene therapy vector for cardiovascular diseases
1School of Bio Sciences and Technology, VIT University, Vellore, India.
Insights
Adeno-associated virus (AAV) gene therapy offers a promising approach to treating cardiovascular diseases, a leading cause of global mortality. This review explores AAV
Area of Science:
- Cardiovascular Medicine
- Gene Therapy
- Molecular Biology
Background:
- Cardiovascular diseases (CVDs) represent a diverse and severe group of conditions contributing significantly to global mortality.
- The high prevalence and severity of CVDs necessitate novel prophylactic and therapeutic strategies.
- Adeno-associated virus (AAV) gene therapy has emerged as a prominent avenue due to its established clinical safety.
Purpose of the Study:
- To review the historical development and current advancements in AAV-mediated gene therapy for cardiovascular diseases.
- To discuss innovations in AAV vector engineering aimed at improving safety and efficacy.
- To provide a comprehensive overview of AAV gene therapy's role in combating cardiovascular pathology.
Main Methods:
- Review of historical data and contemporary research on AAV gene therapy for cardiovascular conditions.
- Analysis of molecular mechanisms in cardiomyocytes and endothelial cells relevant to AAV therapies.
- Exploration of AAV vector engineering strategies to mitigate detargeting, immune responses, and off-target expression.
Main Results:
- AAV gene therapy has shown potential in treating various cardiovascular ailments, including heart failure and vascular diseases.
- Innovations in vector engineering are addressing key challenges such as immune response and targeted delivery.
- The review contextualizes AAV therapies within the broader landscape of cardiovascular pathology and treatment.
Conclusions:
- AAV gene therapy is a rapidly advancing field with significant potential for treating cardiovascular diseases.
- Ongoing research and engineering innovations are crucial for optimizing AAV-based treatments.
- Understanding the molecular basis of cardiovascular diseases is key to leveraging AAV gene therapy effectively.
Abstract:
Cardiovascular diseases pose a unique threat to global mortality because it presents as one of the most diverse conglomerations of pathophysiological conditions that can create significant casualty even without straying into its collateral damage. This puts them right beside obesity and cancer in terms of severity. Their pervasive nature and high prevalence prompted biologists to seek newer prophylactic avenues of addressing this global hazard, among which adeno-associated virus (AAV) gene therapy rose to significant prominence. By virtue of its unrivaled clinical safety quotient, AAVs have been used to rectify various subtypes of cardiovascular ailments, beginning from commonly occurring heart failure to vascular diseases. The review focuses on the history of AAV-mediated gene therapy and contemporary breakthroughs in terms of novel innovations in vector engineering to reduce detargeting, immune response, untimely expression, and so on. We have also focused on the molecular world of cardiomyocytes and endothelial cells but interpreted the therapies in a broader context of cardiovascular pathology. The advances made in each mode of intervention as well as the ones that are beyond the scope of AAV gene therapy or has not been approached through AAV gene therapy as of now have been provided in detail to illustrate the bigger picture of where we stand to combat cardiovascular diseases most efficiently.
